Literature DB >> 22356092

A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus.

S K Thondam, D J Cuthbertson, B S Aditya, I A Macfarlane, J P Wilding, C Daousi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22356092     DOI： 10.1111/j.1365-2265.2012.04368.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN： 0300-0664            Impact factor:   3.478


× No keyword cloud information.
  3 in total

1.  Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity.

Authors:  Jiska van Schaik; Dominique G A Begijn; Laura van Iersel; Yvonne Vergeer; Eelco W Hoving; Babette Peeters; Hanneke M van Santen
Journal:  Obes Facts       Date:  2020-08-11       Impact factor: 3.942

Review 2.  Diagnosis, Background, and Treatment of Hypothalamic Damage in Craniopharyngioma.

Authors:  Eva-Marie Erfurth
Journal:  Neuroendocrinology       Date:  2020-06-24       Impact factor: 4.914

Review 3.  Therapeutic peptides: current applications and future directions.

Authors:  Lei Wang; Nanxi Wang; Wenping Zhang; Xurui Cheng; Zhibin Yan; Gang Shao; Xi Wang; Rui Wang; Caiyun Fu
Journal:  Signal Transduct Target Ther       Date:  2022-02-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.